- Home
- PALI
PALI
Palisade Bio Inc.
as 10-31-2025 9:59am EST
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 212.0M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 10.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $3.44 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palisade Bio Inc. News
PALI Breaking Stock News: Dive into PALI Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Palisade Bio Says First Patients Dosed in Phase 1b Trial of PALI-2108 to Treat Fibrostenotic Crohn's Disease
GlobeNewswire
11 days ago
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
MT Newswires
18 days ago
Palisade Bio Receives Canadian Patent for Composition of Product Candidate PALI-2108
GlobeNewswire
18 days ago
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
GlobeNewswire
22 days ago
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
GlobeNewswire
5 months ago
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
GlobeNewswire
6 months ago
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
GlobeNewswire
6 months ago
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
Compare PALI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PALI Palisade Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.